Sage Research Development vs Net Income From Continuing Ops Analysis

SAGE Stock

USD 5.54 0.19 3.32%

Sage Therapeutic financial indicator trend analysis is much more than just breaking down Sage Therapeutic prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Sage Therapeutic is a good investment. Please check the relationship between Sage Therapeutic Research Development and its Net Income From Continuing Ops accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sage Therapeutic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

For information on how to trade Sage Stock refer to our How to Trade Sage Stock guide.

Research Development vs Net Income From Continuing Ops

Research Development vs Net Income From Continuing Ops Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Sage Therapeutic Research Development account and Net Income From Continuing Ops. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Sage Therapeutic's Research Development and Net Income From Continuing Ops is -0.52. Overlapping area represents the amount of variation of Research Development that can explain the historical movement of Net Income From Continuing Ops in the same time period over historical financial statements of Sage Therapeutic, assuming nothing else is changed. The correlation between historical values of Sage Therapeutic's Research Development and Net Income From Continuing Ops is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Research Development of Sage Therapeutic are associated (or correlated) with its Net Income From Continuing Ops. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income From Continuing Ops has no effect on the direction of Research Development i.e., Sage Therapeutic's Research Development and Net Income From Continuing Ops go up and down completely randomly.

Correlation Coefficient

-0.52

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Research Development

Net Income From Continuing Ops

Most indicators from Sage Therapeutic's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Sage Therapeutic current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sage Therapeutic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

For information on how to trade Sage Stock refer to our How to Trade Sage Stock guide.The current year's Enterprise Value is expected to grow to about 1.8 B, whereas Selling General Administrative is forecasted to decline to about 144.2 M.

	2021	2022	2023	2024 (projected)
Interest Income	2.9M	14.2M	36.1M	37.9M
Net Interest Income	2.9M	14.2M	36.1M	37.9M

Interest Income Net Interest Income

Sage Therapeutic fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Property Plant Equipment	Other Liab	Net Tangible Assets	Common Stock Total Equity	Retained Earnings Total Equity	Capital Surpluse
Total Assets		0.79	0.81	1.0	0.78	-0.67	-0.66	0.41	0.68	0.69	0.35	0.78	1.0	0.88	-0.01	0.94	0.91	0.81	0.82	1.0	0.78	0.09	0.97	0.85	-0.76	0.88
Other Current Liab	0.79		0.99	0.77	0.78	-0.23	-0.83	0.66	0.25	0.73	0.4	0.85	0.77	0.92	-0.1	0.82	0.91	0.96	0.83	0.78	0.69	0.27	0.78	0.88	-0.91	0.89
Total Current Liabilities	0.81	0.99		0.79	0.75	-0.24	-0.83	0.73	0.26	0.75	0.45	0.84	0.8	0.94	-0.12	0.86	0.92	0.96	0.81	0.81	0.68	0.31	0.8	0.88	-0.91	0.9
Total Stockholder Equity	1.0	0.77	0.79		0.76	-0.69	-0.65	0.39	0.7	0.68	0.34	0.77	1.0	0.87	-0.02	0.93	0.9	0.78	0.81	1.0	0.77	0.08	0.97	0.84	-0.74	0.87
Property Plant And Equipment Net	0.78	0.78	0.75	0.76		-0.51	-0.53	0.28	0.53	0.69	0.16	0.7	0.77	0.67	0.33	0.71	0.71	0.84	0.98	0.77	0.66	0.0	0.71	0.59	-0.64	0.68
Net Debt	-0.67	-0.23	-0.24	-0.69	-0.51		0.08	0.06	-1.0	-0.27	0.03	-0.24	-0.69	-0.34	-0.11	-0.5	-0.41	-0.26	-0.46	-0.68	-0.28	-0.05	-0.63	-0.39	0.14	-0.38
Retained Earnings	-0.66	-0.83	-0.83	-0.65	-0.53	0.08		-0.49	-0.09	-0.64	-0.47	-0.97	-0.64	-0.89	0.25	-0.78	-0.86	-0.78	-0.65	-0.66	-0.51	0.01	-0.75	-0.88	0.97	-0.89
Accounts Payable	0.41	0.66	0.73	0.39	0.28	0.06	-0.49		-0.06	0.39	0.35	0.41	0.4	0.56	-0.3	0.46	0.5	0.64	0.28	0.41	0.34	0.72	0.35	0.51	-0.56	0.47
Cash	0.68	0.25	0.26	0.7	0.53	-1.0	-0.09	-0.06		0.28	-0.02	0.25	0.7	0.35	0.12	0.51	0.43	0.28	0.48	0.69	0.29	0.05	0.64	0.4	-0.15	0.4
Non Current Assets Total	0.69	0.73	0.75	0.68	0.69	-0.27	-0.64	0.39	0.28		0.83	0.72	0.69	0.73	0.08	0.84	0.75	0.77	0.76	0.68	0.39	-0.12	0.64	0.63	-0.78	0.73
Non Currrent Assets Other	0.35	0.4	0.45	0.34	0.16	0.03	-0.47	0.35	-0.02	0.83		0.44	0.34	0.49	-0.17	0.6	0.48	0.4	0.27	0.33	0.03	-0.13	0.32	0.41	-0.57	0.47
Other Assets	0.78	0.85	0.84	0.77	0.7	-0.24	-0.97	0.41	0.25	0.72	0.44		0.76	0.9	-0.11	0.86	0.91	0.83	0.8	0.77	0.61	-0.11	0.84	0.88	-0.97	0.92
Cash And Short Term Investments	1.0	0.77	0.8	1.0	0.77	-0.69	-0.64	0.4	0.7	0.69	0.34	0.76		0.87	-0.01	0.93	0.89	0.79	0.81	1.0	0.77	0.1	0.96	0.83	-0.74	0.86
Common Stock Shares Outstanding	0.88	0.92	0.94	0.87	0.67	-0.34	-0.89	0.56	0.35	0.73	0.49	0.9	0.87		-0.14	0.94	0.99	0.9	0.77	0.88	0.7	0.13	0.92	0.97	-0.94	0.99
Non Current Liabilities Total	-0.01	-0.1	-0.12	-0.02	0.33	-0.11	0.25	-0.3	0.12	0.08	-0.17	-0.11	-0.01	-0.14		-0.04	-0.11	0.15	0.27	-0.02	0.07	-0.23	-0.04	-0.23	0.17	-0.11
Other Current Assets	0.94	0.82	0.86	0.93	0.71	-0.5	-0.78	0.46	0.51	0.84	0.6	0.86	0.93	0.94	-0.04		0.96	0.84	0.8	0.93	0.65	0.0	0.94	0.89	-0.87	0.95
Other Stockholder Equity	0.91	0.91	0.92	0.9	0.71	-0.41	-0.86	0.5	0.43	0.75	0.48	0.91	0.89	0.99	-0.11	0.96		0.89	0.81	0.91	0.7	0.07	0.95	0.96	-0.93	1.0
Total Liab	0.81	0.96	0.96	0.78	0.84	-0.26	-0.78	0.64	0.28	0.77	0.4	0.83	0.79	0.9	0.15	0.84	0.89		0.88	0.8	0.7	0.23	0.78	0.82	-0.88	0.87
Property Plant And Equipment Gross	0.82	0.83	0.81	0.81	0.98	-0.46	-0.65	0.28	0.48	0.76	0.27	0.8	0.81	0.77	0.27	0.8	0.81	0.88		0.82	0.7	-0.09	0.79	0.69	-0.75	0.79
Total Current Assets	1.0	0.78	0.81	1.0	0.77	-0.68	-0.66	0.41	0.69	0.68	0.33	0.77	1.0	0.88	-0.02	0.93	0.91	0.8	0.82		0.78	0.1	0.97	0.85	-0.75	0.88
Property Plant Equipment	0.78	0.69	0.68	0.77	0.66	-0.28	-0.51	0.34	0.29	0.39	0.03	0.61	0.77	0.7	0.07	0.65	0.7	0.7	0.7	0.78		0.12	0.73	0.64	-0.6	0.67
Other Liab	0.09	0.27	0.31	0.08	0.0	-0.05	0.01	0.72	0.05	-0.12	-0.13	-0.11	0.1	0.13	-0.23	0.0	0.07	0.23	-0.09	0.1	0.12		0.02	0.18	-0.03	0.03
Net Tangible Assets	0.97	0.78	0.8	0.97	0.71	-0.63	-0.75	0.35	0.64	0.64	0.32	0.84	0.96	0.92	-0.04	0.94	0.95	0.78	0.79	0.97	0.73	0.02		0.91	-0.8	0.94
Common Stock Total Equity	0.85	0.88	0.88	0.84	0.59	-0.39	-0.88	0.51	0.4	0.63	0.41	0.88	0.83	0.97	-0.23	0.89	0.96	0.82	0.69	0.85	0.64	0.18	0.91		-0.9	0.97
Retained Earnings Total Equity	-0.76	-0.91	-0.91	-0.74	-0.64	0.14	0.97	-0.56	-0.15	-0.78	-0.57	-0.97	-0.74	-0.94	0.17	-0.87	-0.93	-0.88	-0.75	-0.75	-0.6	-0.03	-0.8	-0.9		-0.93
Capital Surpluse	0.88	0.89	0.9	0.87	0.68	-0.38	-0.89	0.47	0.4	0.73	0.47	0.92	0.86	0.99	-0.11	0.95	1.0	0.87	0.79	0.88	0.67	0.03	0.94	0.97	-0.93

Click cells to compare fundamentals

Sage Therapeutic Account Relationship Matchups

Sage Therapeutic fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	1.1B	2.2B	1.8B	1.4B	882.3M	873.1M
Other Current Liab	86.6M	46.2M	59.8M	65.0M	62.1M	41.5M
Total Current Liabilities	112.1M	67.2M	85.2M	99.3M	82.7M	59.3M
Total Stockholder Equity	944.7M	2.1B	1.7B	1.3B	799.5M	802.6M
Property Plant And Equipment Net	42.9M	31.8M	19.1M	13.4M	6.4M	11.8M
Net Debt	(89.6M)	(1.6B)	(275.8M)	(150.6M)	(65.8M)	(69.1M)
Retained Earnings	(1.6B)	(1.0B)	(1.5B)	(2.0B)	(2.6B)	(2.4B)
Accounts Payable	15.3M	3.7M	10.5M	19.0M	10.3M	11.5M
Cash	126.7M	1.7B	294.2M	162.7M	71.0M	67.4M
Non Current Assets Total	49.1M	36.9M	24.6M	84.0M	12.9M	20.5M
Non Currrent Assets Other	3.8M	3.3M	4.3M	69.3M	6.5M	8.4M
Other Assets	6.2M	5.1M	5.5M	6.0M	6.9M	7.3M
Cash And Short Term Investments	1.0B	2.1B	1.7B	1.3B	753.2M	829.1M
Common Stock Shares Outstanding	50.8M	53.0M	58.7M	59.3M	59.8M	45.7M
Liabilities And Stockholders Equity	1.1B	2.2B	1.8B	1.4B	882.3M	873.1M
Non Current Liabilities Total	3.7M	27.4M	19.7M	11.1M	4.6M	0.0
Other Current Assets	26.7M	45.6M	39.8M	50.8M	30.3M	21.1M
Other Stockholder Equity	2.6B	3.1B	3.2B	3.3B	3.4B	1.8B
Total Liab	139.5M	86.9M	96.3M	103.9M	82.7M	70.5M
Property Plant And Equipment Gross	42.9M	31.8M	24.1M	19.5M	13.9M	13.2M
Total Current Assets	1.0B	2.1B	1.8B	1.3B	869.4M	852.6M
Accumulated Other Comprehensive Income	1.3M	415K	(2.7M)	(10.2M)	(814K)	(854.7K)
Property Plant Equipment	9.1M	6.8M	19.1M	2.9M	3.3M	5.0M
Other Liab	3.7M	519K	270K	100K	115K	109.3K
Net Tangible Assets	944.7M	2.1B	1.7B	1.3B	1.4B	977.9M
Retained Earnings Total Equity	(1.6B)	(1.0B)	(1.5B)	(2.0B)	(1.8B)	(1.7B)
Short Term Investments	881.7M	438.5M	1.4B	1.1B	682.2M	630.7M
Capital Surpluse	2.6B	3.1B	3.2B	3.3B	3.8B	2.0B
Non Current Liabilities Other	27.4M	19.7M	11.1M	4.6M	5.3M	8.5M
Net Invested Capital	944.7M	2.1B	1.7B	1.3B	799.5M	1.3B
Net Working Capital	923.0M	2.1B	1.7B	1.2B	786.6M	1.3B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

When determining whether Sage Therapeutic is a strong investment it is important to analyze Sage Therapeutic's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Sage Therapeutic's future performance. For an informed investment choice regarding Sage Stock, refer to the following important reports:

How To Invest In Sage

Details

Is Sage Stock a good investment?

Details

What is Sage Therapeutic's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sage Therapeutic. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

For information on how to trade Sage Stock refer to our How to Trade Sage Stock guide.

You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sage Therapeutic. If investors know Sage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sage Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(5.57)

Revenue Per Share

1.76

Quarterly Revenue Growth

3.371

Return On Assets

(0.30)

Return On Equity

(0.49)

The market value of Sage Therapeutic is measured differently than its book value, which is the value of Sage that is recorded on the company's balance sheet. Investors also form their own opinion of Sage Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Sage Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sage Therapeutic's market value can be influenced by many factors that don't directly affect Sage Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Sage Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sage Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sage Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Sage Research Development vs Net Income From Continuing Ops Analysis

Research Development vs Net Income From Continuing Ops

Research Development vs Net Income From Continuing Ops Correlation Analysis

Correlation Coefficient

Research Development

Net Income From Continuing Ops

Sage Therapeutic fundamental ratios Correlations

Sage Therapeutic Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Sage Therapeutic fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Cash And Short Term Investments

Cash	- 1.0	Net Debt
Retained Earnings Total Equity	- 0.97	Other Assets
Other Assets	- 0.97	Retained Earnings
Retained Earnings Total Equity	- 0.94	Common Stock Shares Outstanding
Capital Surpluse	- 0.93	Retained Earnings Total Equity
Retained Earnings Total Equity	- 0.93	Other Stockholder Equity